OAC
CTNM

OMERS Administration Corp’s Contineum Therapeutics CTNM Stock Holding History

OMERS Administration Corp’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$185K Sell
14,200
-20,700
-59% -$278K ﹤0.01% 932
2025
Q4 		$399K Buy
+34,900
New +$398K ﹤0.01% 741

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OMERS Administration Corp's CTNM Position: Q1 2026 in Review

OMERS Administration Corp reduced its Contineum Therapeutics (CTNM) stake by 59% in Q1 2026, selling an estimated $278K and leaving 14,200 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #932.

OMERS Administration Corp first reported a position in CTNM in Q4 2025 and has held it in 2 quarters since. The position peaked at $399K in Q4 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • OMERS Administration Corp held 14,200 shares of Contineum Therapeutics worth $185K as of Q1 2026.
  • OMERS Administration Corp sold 20,700 Contineum Therapeutics shares in Q1 2026, an estimated $278K.
  • Contineum Therapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #932 holding.
  • OMERS Administration Corp first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's Contineum Therapeutics position peaked at $399K in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.